Search research articles
Contact Us
Filters
Showing results (181-190 of 380) with videos related to
Page
of 38
Sort By:
British Journal of Haematology
|
May 18, 2016
Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy
Carmen Martínez, Antonio Díaz-López, Mercedes Rodriguez-Calvillo, et al.
Blood
|
December 4, 2012
Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation
Damien Roos-Weil, Sascha Dietrich, Ariane Boumendil, et al.
British Journal of Haematology
|
February 23, 2018
Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party
Ali Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Blood
|
January 10, 2025
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
Joshua D Brody, Judit Jørgensen, David Belada, et al.
Journal of Clinical Apheresis
|
June 21, 2017
UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy
Kenneth W Douglas, Maria Gilleece, Patrick Hayden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
Martin Hutchings, Anna Sureda, Francesc Bosch, et al.
Bone Marrow Transplantation
|
January 4, 2026
Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP
Patricia López-Pereira, Ali Bazarbachi, Ambroise Marçais, et al.
Oncotarget
|
August 4, 2016
Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features
Laura Palomo, Olga Garcia, Montse Arnan, et al.
Lancet (London, England)
|
September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Martin Hutchings, Rogier Mous, Michael Roost Clausen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2008
Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation
Celso A Rodrigues, Guillermo Sanz, Claudio G Brunstein, et al.
Page
of 38
Search research articles
Search
Showing results (181-190 of 380) with videos related to
Sort By:
Page
of 38
British Journal of Haematology
|
May 18, 2016
Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy
Carmen Martínez, Antonio Díaz-López, Mercedes Rodriguez-Calvillo, et al.
Blood
|
December 4, 2012
Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation
Damien Roos-Weil, Sascha Dietrich, Ariane Boumendil, et al.
British Journal of Haematology
|
February 23, 2018
Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party
Ali Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Blood
|
January 10, 2025
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
Joshua D Brody, Judit Jørgensen, David Belada, et al.
Journal of Clinical Apheresis
|
June 21, 2017
UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy
Kenneth W Douglas, Maria Gilleece, Patrick Hayden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
Martin Hutchings, Anna Sureda, Francesc Bosch, et al.
Bone Marrow Transplantation
|
January 4, 2026
Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP
Patricia López-Pereira, Ali Bazarbachi, Ambroise Marçais, et al.
Oncotarget
|
August 4, 2016
Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features
Laura Palomo, Olga Garcia, Montse Arnan, et al.
Lancet (London, England)
|
September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Martin Hutchings, Rogier Mous, Michael Roost Clausen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2008
Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation
Celso A Rodrigues, Guillermo Sanz, Claudio G Brunstein, et al.
Page
of 38